| Molecular formula | C192H289N47O61 |
|---|
| Molecular weight | 4232 g/mol |
|---|
| Registered trials | 24 |
|---|
| PubChem CID | 171378821 |
|---|
Survodutide is not an approved therapy in the United States and remains under clinical investigation. No FDA label exists yet, so questions about safety, efficacy, or approved use cannot be answered from official prescribing information.
What survodutide is
Survodutide is a large, synthetic peptide compound with the molecular formula C192H289N47O61 and a molecular weight of about 4,232 daltons. Its structure is catalogued in PubChem under CID 171378821. No approved brand name, drug class label, or mechanism-of-action statement currently exists for this compound because it has not cleared FDA review.
Regulatory status
Survodutide is classified as unapproved and investigational. It has no FDA-approved indication, labeling, or brand name, and any use outside of registered clinical trials falls outside approved medical practice.
Clinical trial footprint
Survodutide appears in 24 registered studies on ClinicalTrials.gov. Sampled trials include a completed study evaluating survodutide in Japanese adults living with obesity and a completed trial assessing weight loss in adults with overweight or obesity who do not have diabetes. A third trial, called LIVERAGE, is currently recruiting participants with NASH/MASH-related liver cirrhosis to study survodutide in that population.
FAQ
Survodutide is a large synthetic peptide compound identified by PubChem CID 171378821, with a molecular weight of about 4,232 daltons. It is currently investigational and has no FDA-approved label, brand name, or confirmed mechanism of action.
No. Survodutide is unapproved and remains in the research and clinical trial stage. It has not been reviewed or cleared by the FDA for any medical use.
Registered trials have examined survodutide in adults with obesity or overweight and in people with NASH/MASH-related liver cirrhosis. These are research studies, and no conclusions about approved use can be drawn from them.
As of the data reviewed, 24 studies referencing survodutide are registered on ClinicalTrials.gov. These include both completed and actively recruiting trials across different patient populations.
Survodutide has the molecular formula C192H289N47O61 and a molecular weight of approximately 4,232 daltons. Its full structure is catalogued in PubChem under CID 171378821.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication.
Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.
Sources: ClinicalTrials.gov PubChem
Updated 2026-08-03